CAM
EGRX

Capstone Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Capstone Asset Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$213K Sell
2,698
-110
-4% -$9K 0.01% 1482
2017
Q1 		$233K Sell
2,808
-200
-7% -$14.9K 0.01% 1458
2016
Q4 		$239K Sell
3,008
-3,492
-54% -$254K 0.01% 1468
2016
Q3 		$455K Buy
+6,500
New +$360K 0.01% 1030

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Capstone Asset Management's EGRX Position: Q2 2017 in Review

Capstone Asset Management reduced its Eagle Pharmaceuticals, Inc. (EGRX) stake by 3.9% in Q2 2017, selling an estimated $9K and leaving 2,698 shares worth $213K. The position accounts for 0.01% of the portfolio, ranked #1482.

Capstone Asset Management first reported a position in EGRX in Q3 2016 and has held it in 4 quarters since. The position peaked at $455K in Q3 2016. 175 funds tracked by Wall St. Rank hold EGRX as of Q2 2017.

  • Capstone Asset Management held 2,698 shares of Eagle Pharmaceuticals, Inc. worth $213K as of Q2 2017.
  • Capstone Asset Management sold 110 Eagle Pharmaceuticals, Inc. shares in Q2 2017, an estimated $9K.
  • Eagle Pharmaceuticals, Inc. made up 0.01% of Capstone Asset Management's portfolio in Q2 2017, its #1482 holding.
  • Capstone Asset Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2016 and has held it in 4 quarters since.
  • Capstone Asset Management's Eagle Pharmaceuticals, Inc. position peaked at $455K in Q3 2016.
  • 175 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2017.

Based on Capstone Asset Management's 13F filing for Q2 2017, filed 10 Jul 2017.